Financial Performance & Growth - The company's last twelve months (LTM) global proforma revenue is $564 million[6] - The company is experiencing above-market revenue growth, with seven quarters of mid-single-digit or higher growth[7] - The company's organic growth is projected at 7.0% in 2025[11] - The company's Adjusted EBITDA margin is steadily increasing, projected to reach 20.2% in 2025[14] - Cash from operations is increasing, with 2025 projected to be nearly double that of 2024[18] - Net leverage ratio is decreasing, projected to be less than 2.5x by the end of 2025[28] Market & Strategy - The company operates in a $6.4 billion addressable market[6] - The company has a diversified portfolio across Pain Treatments, Surgical Solutions, and Restorative Therapies[5, 20] - The company is focused on margin expansion by leveraging mid-70s gross margin and cost efficiencies[7, 25] - The company aims to nearly double 2024 free cash flow in 2025, with a cash flow yield of approximately 60%[28]

Financial Performance & Guidance - Methode Electronics reported FY25 sales of $1.05 billion[13, 30] and adjusted EBITDA of $43 million[30] - The company's Q4 FY25 free cash flow reached $26 million, the highest since FY23[8, 30] - FY26 guidance projects sales between $900 million and $1 billion[36], with a midpoint of $950 million[34], and EBITDA between $70 million and $80 million[30, 36], with a midpoint of $75 million[34], representing a 100%+ increase in EBITDA despite ~$100 million lower sales[10, 37] - The company anticipates $58 - $63 million in Depreciation and Amortization, $24 - $29 million in CapEx, $21 - $23 million in Interest Expense and $17 - $21 million in Tax Expense for FY26[36] Business Segments & Growth - In FY25, Automotive segment accounted for 45% of sales, Industrial 40%, and Interface 15%[13] - User Interface solutions represented 45% of sales, Lighting 27%, Power 24%, and Sensors 2%[13, 19] - The company achieved record power product sales in data centers exceeding $80 million in FY25, with similar or greater sales expected in FY26[8, 37] Market & Strategic Outlook - A reset of EV sales is expected in FY26 due to a slowdown in the North American market, particularly driven by Stellantis, with a return to growth anticipated in FY27[9] - Awards of $1.0+ billion in annual sales were secured from FY22 to FY25[30] - The company is focused on transformation, prioritizing improved execution before growth, emphasizing "Earning the Right"[8, 26, 37]

Clinical Programs & Data - Tenaya Therapeutics has 3 clinical-stage programs focused on heart disease [9] - TN-201 for MYBPC3-associated HCM plans data release including longer-term follow-up for Cohort 1 (3E13 vg/kg) and initial safety and biopsy results for Cohort 2 (6E13 vg/kg) in Q4'25 [15] - TN-401 for PKP2-associated ARVC plans data release will include initial Cohort 1 (3E13 vg/kg) data focused on safety and biopsy results in Q4'25 [16] - Interim Cohort 1 TN-201 data showed improvements in ≥ 1 measures of hypertrophy in two of three patients [17] Disease & Patient Populations - MYBPC3-associated HCM is estimated to affect 120,000 people in the U S alone [22] - Approximately 57% of identified genetic variants underlying familial HCM are MYBPC3 mutations [22] - Over 30% of genetic variants underlying childhood-onset HCM are MYBPC3 mutations [22] - PKP2-associated ARVC is estimated to affect >70,000 people in the U S [75] - In ARVC patients, >15% of heart-related deaths in patients < 35 are due to ARVC [75] - In ARVC patients, 23% of ARVC patients present with sudden cardiac death [75] - In ARVC patients, 40% of ARVC patients carry pathogenic PKP2 mutations [75] Capabilities & Milestones - Tenaya has cGMP AAV manufacturing scale achieved; 1000L clinical supply for TN-201 and TN-401 ready [115]

Company Overview - Eagle Point Income Company (EIC) aims to generate high current income and capital appreciation by investing primarily in junior debt tranches of CLOs, with a focus on BB-rated CLO debt[13] - As of June 30, 2025, the total market capitalization of EIC is $501 million[13] - EIC pays a monthly distribution of $0.13 per share, resulting in a distribution rate of 12.0%[13] - The Adviser and Senior Investment Team have approximately $0.8 million invested in EIC, EICA, EICB and EICC[23] CLO Market and Strategy - BB-rated CLO debt has historically exhibited a low default rate of approximately 4 bps per annum from 1994 through Q1 2025[14, 29] - The cumulative default rate on BB-rated CLO debt was 1.1% from 1994 through Q1 2025[29] - The company focuses primarily in junior debt tranches of CLOs, with a focus on BB-rated CLO debt[31] - The CLO market is the largest source of capital for the US senior secured loan market[40] - From 1992 through 2024, the S&P UBS Leveraged Loan Index generated positive total returns in 30 of the 33 full calendar years[42] Portfolio Information (Q2 2025) - The weighted average effective yield on the CLO portfolio was 10.63%[52] - The company's CLO debt investments totaled $379.8 million, and CLO equity investments totaled $127.1 million[52] - The company has exposure to 1,464 unique underlying borrowers[57]

Financial Performance & Growth - Clover Health anticipates insurance revenue of $1.8 billion to $1.875 billion for full year 2025[50] - The company projects Adjusted EBITDA between $50 million and $70 million for full year 2025[9, 50] - Clover Health expects a 32% year-over-year increase in Medicare Advantage (MA) membership in 2025[9, 44] - Clover Health's Insurance Benefits Expense Ratio (BER) for the first half of 2025 was 87.3%[24] Clover Assistant & Clinical Outcomes - Clover Assistant (CA) is associated with earlier diagnosis of Chronic Kidney Disease (CKD) by approximately 18 months on average[18] - Clover Assistant is associated with 15% lower all-cause hospitalizations and 18% lower 30-day readmissions for members with Chronic Obstructive Pulmonary Disease (COPD)[18, 20] - Clover Health achieved a 4.94 out of 5 Stars on HEDIS measures for Star Rating year 2025, the top-performing score on core HEDIS measures for Medicare Advantage plans with over 2,000 members nationwide[18] Strategic Initiatives - Clover Health is focused on a ~$500 billion market with over 35 million seniors enrolled in Medicare Advantage[8] - Clover Health's Counterpart Health subsidiary aims to expand the company's care model to more plans and providers[8] - Approximately 97% of Clover Health's membership is enrolled in PPO plans[8, 49]

Company Overview - Beasley Media Group's future growth will be driven by operational efficiency in its core business and expansion of its digital capabilities[12] - The company operates in 12 US markets[13] - The company's multimedia platform enables local businesses to maximize audience reach[28] Financial Performance - Q2 2025 - Total net revenue was $53 million[47] - Digital revenue accounted for 25% of total net revenue[23] - Same-station digital revenue grew by 81% year-over-year[23] - Station Operating Income (SOI) was $82 million[47] - Adjusted EBITDA was $47 million[47] Revenue Mix - Audio revenue for Q2 2025 was $398 million[23] - Digital revenue for Q2 2025 was $132 million[22] - Local advertisers accounted for 76% of Q2 2025 revenue[25]

Financial Performance & Position - HighPeak Energy reported Q2 2025 production of 48600 barrels of oil equivalent per day (MBoe/d)[14] - The company's Q2 2025 unhedged EBITDAX per BOE was $3358[14] - Q2 2025 EBITDAX totaled $156 million[14] - As of June 30, 2025, the company's pro forma total debt was $12 billion, with a net debt of $1032 billion[16] - The company's total liquidity stood at $268 million, including $168 million in cash and cash equivalents[16] Debt & Hedging - HighPeak Energy extended its Term Loan and Revolving Credit Facility maturities to September 2028 and upsized the Term Loan to $12 billion[21] - Approximately 53% of the company's oil volumes and 89% of gas volumes are hedged for the second half of 2025[25] Operational Efficiency - The company achieved savings of approximately $400000 per well by using Lorin Pad Simulfrac[29] - Simulfrac savings led to a 10% reduction in completion costs[30] - Solar savings from June to December 2024 amounted to $809487, with a CO2 reduction of 4616 metric tons[34] Asset Base - HighPeak Energy has over 143000 net acres[14,35] - The company has over 1000 sub $50/Bbl break-even locations in primary zones[14,35]

Financial Performance - Broadwind's total revenue increased by 7.6% year-over-year in Q2 2025, reaching $39.2 million[16], driven by strong demand from the wind and industrial verticals[12] - Gross margin decreased to 10.1% in Q2 2025 due to manufacturing inefficiencies in the Heavy Fabrications segment and lower capacity utilization within the Gearing segment[12] - Adjusted EBITDA margin decreased to 5.3% year-over-year, amounting to $2.1 million in Q2 2025, as labor was added to support increased volumes in the wind and power generation verticals[12, 15] - GAAP Net Income turned into a loss of $1.0 million in Q2 2025, compared to a profit of $0.5 million in Q2 2024[17] Segment Performance - Heavy Fabrications segment revenue increased due to wind tower and repowering adapter sales, reaching $25.0 million[20, 23] - Heavy Fabrications segment EBITDA margin decreased to 11.4% in Q2 2025[20] - Gearing segment revenue declined by 30% year-over-year to $7.3 million in Q2 2025, but orders increased by 45% to $6.8 million[26, 27, 28] - Industrial Solutions segment revenue increased by 13.9% year-over-year to $7.4 million, with orders up by 207% to $13.9 million[32, 33, 34] Balance Sheet - Net working capital investment increased by 24% year-over-year to $42.5 million in Q2 2025[40, 43] - Total inventory increased to $51.4 million in Q2 2025[45] - Cash and LOC availability at quarter-end was $14.9 million[41]

Company Overview - Euroholdings Ltd was spun off from Euroseas Ltd on March 17, 2025[10] - The spin-off included a fleet of two debt-free vessels and approximately $14 million in cash from the sale of M/V Diamantis P[10] - Marla Investments Inc acquired 51.04% of Euroholdings' outstanding common shares from the Pittas family on June 23, 2025[10, 16] - The company declared a second quarterly dividend of $0.14 per share for Q2 2025[15] Strategic Shift - Euroholdings plans to focus on the tanker market, initially pursuing medium range ("MR") product tanker investments[11, 12] - Approximately $15 million is available for equity investment in the tanker sector[12] Financial Performance (Q2 2025) - Net Revenues were $2.92 million[14, 43] - Net Income was $0.82 million[14, 43] - Adjusted EBITDA was $0.81 million[14, 43] Containership Fleet - The current fleet consists of 2 vessels with a total capacity of 3,171 TEU and an average age of 26.9 years[38] - Charter coverage is approximately 82% for the remaining 6 months of 2025 and about 40% for 2026[38]

Financial Performance - Nauticus' current revenue forecast indicates sequential growth[10] - Year-over-year customer diversification increased by 200%[11] - Nauticus generated a $1.6 million increase in revenues year-over-year[11] - The company's net loss attributable to common stockholders (GAAP) for the six months ended June 30, 2025, was $(15,021,363)[23] Operational Highlights - An ROV completed its project on a drill ship and moved to the U S Northeast Coast for offshore windfarm inspections[12] - A second ROV completed projects for nine different customers off the U S Gulf Coast[12] - Aquanaut Vehicle 2 completed operational readiness and is ready to work on the Gulf Coast vessel[12] Market Opportunities - The offshore oil & gas AUV/ROV market is projected to grow from $1 72 billion in 2023 to $2 13 billion in 2030[9] - The offshore wind AUV/ROV market is projected to grow from $0 58 billion in 2023 to $1 52 billion in 2030[9] - The military & defense AUV/ROV market was $2 12 billion in 2023 and is projected to reach $2 83 billion in 2030[9] - The port management AUV/ROV market is projected to grow from $1 12 billion in 2023 to $1 32 billion in 2030[9]